The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations.
作者信息
Elens Laure, Hesselink Dennis A, van Schaik Ron H N, van Gelder Teun
出版信息
Br J Clin Pharmacol. 2013 Jun;75(6):1545-7. doi: 10.1111/bcp.12038.
Abstract
摘要
相似文献
1
The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations.
Br J Clin Pharmacol. 2013 Jun;75(6):1545-7. doi: 10.1111/bcp.12038.
2
A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
Clin Chem. 2011 Nov;57(11):1574-83. doi: 10.1373/clinchem.2011.165613. Epub 2011 Sep 8.
3
"What do we know about tacrolimus pharmacogenetics in transplant recipients?".
Pharmacogenomics. 2018 May;19(7):593-597. doi: 10.2217/pgs-2018-0035. Epub 2018 Apr 27.
4
Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations.
Pharmacogenet Genomics. 2011 Apr;21(4):179-84. doi: 10.1097/FPC.0b013e32833ea085.
5
Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.
Ther Drug Monit. 2014 Feb;36(1):71-9. doi: 10.1097/FTD.0b013e31829da6dd.
6
Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
Ther Drug Monit. 2013 Oct;35(5):608-16. doi: 10.1097/FTD.0b013e318296045b.
7
Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
Transplantation. 2012 Nov 27;94(10):1013-9. doi: 10.1097/TP.0b013e31826bc400.
8
Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients.
Pharmacogenet Genomics. 2018 Feb;28(2):41-48. doi: 10.1097/FPC.0000000000000321.
9
CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Clin Transplant. 2016 Sep;30(9):1074-81. doi: 10.1111/ctr.12790. Epub 2016 Jul 11.
10
Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose.
Br J Clin Pharmacol. 2019 Aug;85(8):1852-1854. doi: 10.1111/bcp.13958. Epub 2019 Jun 12.
引用本文的文献
1
Tacrolimus Trough Concentrations are Not Impacted by Epstein-Barr Virus Serology and Viral Load in Pediatric Liver Transplant Recipients.
Eur J Drug Metab Pharmacokinet. 2025 Jun 17. doi: 10.1007/s13318-025-00954-3.
2
Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome.
Alzheimers Dement. 2025 Mar;21(3):e70034. doi: 10.1002/alz.70034.
3
Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?
Transpl Int. 2021 Dec;34(12):2442-2458. doi: 10.1111/tri.14115. Epub 2021 Oct 28.
4
Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function.
Clin Transl Sci. 2021 Jul;14(4):1292-1302. doi: 10.1111/cts.12970. Epub 2021 Jan 27.
5
Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation.
Curr Drug Metab. 2018;19(6):513-522. doi: 10.2174/1389200219666180129151948.
6
Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation.
Front Pharmacol. 2017 Jun 8;8:358. doi: 10.3389/fphar.2017.00358. eCollection 2017.
7
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.
Br J Clin Pharmacol. 2017 Jul;83(7):1457-1465. doi: 10.1111/bcp.13248. Epub 2017 Feb 27.
8
Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype.
Pharmacogenomics J. 2017 Dec;17(6):556-562. doi: 10.1038/tpj.2016.49. Epub 2016 Jul 5.
9
External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.
Br J Clin Pharmacol. 2016 May;81(5):891-907. doi: 10.1111/bcp.12830. Epub 2016 Feb 26.
10
Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children.
Clin Pharmacokinet. 2015 Dec;54(12):1183-204. doi: 10.1007/s40262-015-0298-7.
本文引用的文献
1
Validation of tacrolimus equation to predict troughs using genetic and clinical factors.
Pharmacogenomics. 2012 Jul;13(10):1141-7. doi: 10.2217/pgs.12.98.
2
A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
Clin Chem. 2011 Nov;57(11):1574-83. doi: 10.1373/clinchem.2011.165613. Epub 2011 Sep 8.
3
Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
Pharmacogenomics. 2011 Oct;12(10):1383-96. doi: 10.2217/pgs.11.90. Epub 2011 Sep 8.
4
Dosing equation for tacrolimus using genetic variants and clinical factors.
Br J Clin Pharmacol. 2011 Dec;72(6):948-57. doi: 10.1111/j.1365-2125.2011.04039.x.
5
Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial.
Transplantation. 2008 Oct 27;86(8):1043-51. doi: 10.1097/TP.0b013e318186f98a.
6
Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.
Drug Metab Dispos. 2000 Feb;28(2):125-30.
Zotero 插件